Garth Powis Selected Research

2- amino- 3- (4'- N,N- bis(2- chloroethyl)amino)phenylpropionic acid N-oxide

7/2010	Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.
7/2010	Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.
4/2009	The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.
1/2008	Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.
11/2005	Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo.
5/2005	Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.
3/2004	Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Garth Powis Research Topics

Disease

78	Neoplasms (Cancer) 10/2020 - 09/2002
31	Hypoxia (Hypoxemia) 10/2020 - 09/2002
10	Breast Neoplasms (Breast Cancer) 03/2016 - 09/2002
6	Neoplasm Metastasis (Metastasis) 09/2019 - 09/2002
6	Colonic Neoplasms (Colon Cancer) 01/2019 - 01/2004
5	Colorectal Neoplasms (Colorectal Cancer) 06/2016 - 07/2003
5	Pancreatic Neoplasms (Pancreatic Cancer) 03/2012 - 03/2004
5	Glioma (Gliomas) 02/2011 - 08/2006
4	Stomach Neoplasms (Stomach Cancer) 12/2016 - 05/2012
4	Carcinogenesis 01/2009 - 04/2003
3	Melanoma (Melanoma, Malignant) 12/2015 - 08/2010
3	Glioblastoma (Glioblastoma Multiforme) 04/2011 - 06/2010
3	Lung Neoplasms (Lung Cancer) 07/2010 - 05/2008
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2010 - 09/2005
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2015 - 03/2003
2	Adenocarcinoma 01/2014 - 04/2009
2	Sarcoma (Soft Tissue Sarcoma) 01/2014 - 02/2012
2	Adenocarcinoma of Lung 07/2010 - 05/2008
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 07/2010 - 03/2004
2	Hyperglycemia 01/2009 - 09/2005
2	Carcinoma (Carcinomatosis) 03/2003 - 09/2002
1	Fibrosis (Cirrhosis) 05/2016
1	Non-alcoholic Fatty Liver Disease 05/2016
1	Hepatocellular Carcinoma (Hepatoma) 05/2016
1	Polyps 01/2014

Drug/Important Bio-Agent (IBA)

17	ThioredoxinsIBA 08/2011 - 09/2002
16	Proteins (Proteins, Gene)FDA Link 12/2016 - 09/2002
14	Transcription Factors (Transcription Factor)IBA 11/2019 - 03/2003
12	Oxygen (Dioxygen)IBA 05/2016 - 09/2002
11	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2019 - 09/2002
8	PX-866IBA 04/2011 - 07/2004
7	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 03/2011 - 09/2007
7	2- amino- 3- (4'- N,N- bis(2- chloroethyl)amino)phenylpropionic acid N-oxideIBA 07/2010 - 03/2004
5	Hypoxia-Inducible Factor 1IBA 10/2020 - 09/2002
5	Biomarkers (Surrogate Marker)IBA 12/2016 - 06/2005
4	Small Interfering RNA (siRNA)IBA 01/2015 - 03/2008
4	Phosphatidylinositols (Phosphatidylinositol)IBA 02/2013 - 09/2004
4	Thioredoxin-Disulfide ReductaseIBA 06/2006 - 02/2003
3	EnzymesIBA 10/2020 - 01/2016
3	CytokinesIBA 11/2019 - 08/2010
3	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 05/2004
3	Messenger RNA (mRNA)IBA 01/2014 - 10/2002
3	Dihydrotachysterol (AT 10)IBA 07/2010 - 01/2004
3	Protein Isoforms (Isoforms)IBA 05/2009 - 10/2006
3	Glucose (Dextrose)FDA LinkGeneric 01/2009 - 03/2004
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 05/2008 - 09/2004
3	WortmanninIBA 09/2007 - 01/2004
2	RNA (Ribonucleic Acid)IBA 11/2019 - 05/2012
2	InterleukinsIBA 11/2019 - 08/2010
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 06/2016
2	Ligases (Synthetase)IBA 05/2016 - 12/2008
2	Monoclonal AntibodiesIBA 03/2016 - 12/2014
2	Trastuzumab (Herceptin)FDA Link 03/2016 - 01/2015
2	VemurafenibIBA 12/2015 - 02/2013
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2015 - 05/2009
2	DNA (Deoxyribonucleic Acid)IBA 01/2015 - 01/2014
2	MethyltransferasesIBA 01/2014 - 02/2013
2	4- imino- 1,3- diazabicyclo(3.1.0)hexan- 2- oneIBA 06/2012 - 03/2012
2	Glutathione (Reduced Glutathione)IBA 06/2012 - 03/2012
2	PlatinumIBA 02/2011 - 03/2008
2	Protein Kinases (Protein Kinase)IBA 03/2010 - 04/2003
2	4- dodecyl- N- (1,3,4- thiadiazol- 2- yl)benzenesulfonamideIBA 03/2010 - 06/2009
2	TensinsIBA 05/2008 - 09/2007
2	OxidesIBA 01/2008 - 03/2004
2	propionic acid (potassium propionate)IBA 01/2008 - 03/2004
2	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 10/2006 - 04/2003
2	1- ((1- O- octadecyl- 2- O- methylglycero)phospho)- 3- deoxy- myo- inositolIBA 10/2006 - 01/2004
2	Phosphotransferases (Kinase)IBA 08/2006 - 09/2004
2	Oxidoreductases (Dehydrogenase)IBA 06/2006 - 02/2003
2	ParaffinIBA 06/2005 - 07/2003
2	DisulfidesIBA 01/2005 - 03/2003
2	LipidsIBA 09/2004 - 11/2003
1	Small Cytoplasmic RNAIBA 11/2019
1	Interleukin-8 (Interleukin 8)IBA 11/2019
1	GlycogenIBA 11/2019
1	Fluorescent Dyes (Fluorescent Probes)IBA 09/2019
1	Cathepsin BIBA 09/2019
1	CathepsinsIBA 09/2019
1	Multifunctional EnzymesIBA 01/2018
1	Monomeric GTP-Binding ProteinsIBA 12/2016
1	Cyclin DIBA 06/2016
1	UbiquitinIBA 05/2016
1	Chemokine CCL5IBA 05/2016
1	Tumor Biomarkers (Tumor Markers)IBA 03/2016
1	Fructose-Bisphosphate Aldolase (Aldolase)IBA 01/2016
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 12/2014
1	Peptide Hydrolases (Proteases)FDA Link 12/2014
1	DisintegrinsIBA 12/2014
1	Metalloproteases (Metalloproteinases)IBA 12/2014
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2014
1	Bile Acids and Salts (Bile Acids)IBA 01/2014
1	hydrogen sulfite (bisulfite)IBA 01/2014
1	LigandsIBA 06/2013
1	PLX 4720IBA 02/2013
1	mercury orangeIBA 06/2012

Therapy/Procedure

24	Therapeutics 01/2017 - 12/2003
3	Radiotherapy 03/2011 - 10/2006
3	Aftercare (After-Treatment) 11/2005 - 01/2005
2	Precision Medicine 01/2017 - 12/2016
2	Drug Therapy (Chemotherapy) 07/2010 - 12/2003